Marion C. Dickson
Middlesex, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.
Journal: British journal of clinical pharmacology
Published: January 05, 2021
Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study.
Journal: Experimental dermatology
Published: December 11, 2019
GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin.
Journal: British journal of pharmacology
Published: August 13, 2018
Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Journal: Bioorganic & medicinal chemistry letters
Published: August 09, 2018
Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia.
Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia.
Journal: British journal of haematology
Published: August 04, 2017
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.
Journal: Lupus
Published: April 09, 2016
Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Journal: Experimental dermatology
Published: February 09, 2016
A model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: a potential translational model for drug development.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: December 17, 2014
The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
Journal: Journal of autoimmunity
Published: July 10, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026